Stay updated on Nivolumab & Lenvatinib in HCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Lenvatinib in HCC Clinical Trial page.

Latest updates to the Nivolumab & Lenvatinib in HCC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded the hepatocellular carcinoma term and a Genetic and Rare Diseases Information Center resource; updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page's revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check70 days agoChange DetectedAdded Revision: v3.4.2 and removed older notices about government funding and NIH Clinical Center operating status. These are administrative updates that do not modify the study details.SummaryDifference0.4%

- Check77 days agoChange DetectedA new government funding notice was added to the page to inform users about potential updates and refer them to cc.nih.gov and opm.gov. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check84 days agoChange DetectedMinor UI and metadata updates, including Show glossary and small phrasing changes such as capitalization of 'Met QC Criteria'/'met QC Criteria' and 'No FEAR Act data', along with a new 'Revision: v3.4.0' note. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Nivolumab & Lenvatinib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Lenvatinib in HCC Clinical Trial page.